Reglagene Holding, Inc. products
Reglagene - Novel Therapeutics Lacking for Brain Cancer
Only 4 of the 217 FDA-approved oncology medicines are indicated for life-threatening brain cancers. The most recent approval was in 2009, but this medicine did not extend life expectancy. Patients deserve better therapies that extend life and improve quality of life. The Reglagene team is developing a first-in-class blood–brain barrier (BBB) penetrant medicine that effectively fights brain cancer.
Pipeline
Anti-Cancer for Microtubule Targeting Agent
RGN3118 is a potent, orally administered, blood-brain barrier penetrant therapy that has been optimized for the treatment of high-grade gliomas, such as glioblastoma as well as brain metastases from breast, lung, and melanoma cancers.
Reglagene - Age Related Macular Degeneration for Microtubule Targeting Agent
RGNXXXX is a potent, topical eye drop for the treatment of wet AMD. The anti-neovascular effects reduces leaky blood vessels in the eyes.
Reglagene - Anti-Infectivity & Anti-Inflammation for Microtubule Targeting Agent
RGNXXXX is a potent, orally administered, blood-brain barrier penetrant therapy that is being optimized for the treatment of anti-infectivity and neuro-inflammation, such as acute COVID-19 and neuro-inflammatory diseases, respectfully.